Sangamo Therapeutics (NASDAQ: SGMO) reported Q2 EPS of ($0.08), $0.06 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $18.3 million versus the consensus estimate of $29.9 million.

Financial Guidance for 2025 Reiterated

On a GAAP basis, we continue to expect total operating expenses in the range of approximately $135 million to $155 million in 2025, which includes estimated non-cash stock-based compensation expense, and depreciation and amortization.

We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $7 million, and estimated depreciation and amortization of approximately $3 million, in the range of approximately $125 million to $145 million in 2025, consistent with 2024. This reflects our intention to operate a lean neurology-focused business and to continue advancing isaralgagene civaparvovec towards a potential BLA submission, while continuing to engage in business development negotiations for a potential Fabry commercialization agreement.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.